Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle progression in the developing retina
The Journal of Pathology · 2023-04 · 259 (4) · 441-454
DOI: 10.1002/path.6056 ↗At a glance
Journal article in The Journal of Pathology, published online on 2023-02-09. Written by Nicholas Owen and 9 co-authors. Institution: UCL Institute of Ophthalmology, University College London, London, UK. Major MEDLINE topics: Zebrafish, Cell Polarity. Cited 16 times so far (Crossref); 70 references. The full text is freely available (open access, CC BY 4.0). Funded by: Wellcome Trust, Moorfields Eye Charity.
Abstract (original language)
The crumbs cell polarity complex plays a crucial role in apical–basal epithelial polarity, cellular adhesion, and morphogenesis. Homozygous variants in human CRB1 result in autosomal recessive Leber congenital amaurosis (LCA) and retinitis pigmentosa (RP), with no established genotype–phenotype correlation. The associated protein complexes have key functions in developmental pathways; however, the underlying disease mechanism remains unclear. Using the oko meduzy m289/m289 ( crb2a −/− ) zebrafish, we performed integrative transcriptomic (RNA‐seq data) and methylomic [reduced representation bisulphite sequencing (RRBS)] analysis of whole retina to identify dysregulated genes and pathways. Delayed retinal cell specification was identified in both the crb2a −/− zebrafish and CRB1 patient‐derived retinal organoids, highlighting the dysfunction of cell cycle modulation and epigenetic transcriptional control. Differential DNA methylation analysis revealed novel hypermethylated pathways involving biological adhesion, Hippo, and transforming growth factor β (TGFβ) signalling. By integrating gene expression with DNA methylation using functional epigenetic modules (FEM), we identified six key modules involving cell cycle control and disturbance of TGFβ, bone morphogenetic protein (BMP), Hippo, and SMAD protein signal transduction pathways, revealing significant interactome hotspots relevant to crb2a function and confirming the epigenetic control of gene regulation in early retinal development, which points to a novel mechanism underlying CRB1 ‐retinopathies. © 2023 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- UCL Institute of Ophthalmology, University College London, London, UK.
- The Francis Crick Institute, London, UK.
- Medical Genomics, UCL Cancer Institute, University College London, London, UK.
- Department of Ophthalmology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
- Department of Genetics, Moorfields Eye Hospital NHS Foundation Trust, London, UK.
ORCID profiles: Nicholas Owen, Mariya Moosajee
Funding
- Wellcome Trust
- Moorfields Eye Charity
Cite
APA
Owen, N., Toms, M., Tian, Y., Toualbi, L., Richardson, R., Young, R., Tracey-White, D., Dhami, P., Beck, S., & Moosajee, M. (2023). Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle progression in the developing retina. The Journal of Pathology, 259(4), 441-454. https://doi.org/10.1002/path.6056
Vancouver
Owen N, Toms M, Tian Y, Toualbi L, Richardson R, Young R, et al. Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle progression in the developing retina. The Journal of Pathology. 2023;259(4):441-454. doi:10.1002/path.6056
BibTeX
@article{Owen2023,
author = {Owen, Nicholas and Toms, Maria and Tian, Yuan and Toualbi, Lyes and Richardson, Rose and Young, Rodrigo and Tracey-White, Dhani and Dhami, Pawan and Beck, Stephan and Moosajee, Mariya},
title = {Loss of the crumbs cell polarity complex disrupts epigenetic transcriptional control and cell cycle progression in the developing retina},
journal = {The Journal of Pathology},
year = {2023},
volume = {259},
number = {4},
pages = {441--454},
doi = {10.1002/path.6056}
}
EUVIMED